Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
2.

Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial.

van Doeveren T, van Leeuwen PJ, Aben KKH, van der Aa M, Barendrecht M, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Hirdes W, Kooistra A, Kroon B, Leliveld AM, Meijer RP, van Melick H, Merks B, de Reijke TM, de Vries P, Wymenga LFA, Wijsman B, Boormans JL.

Contemp Clin Trials Commun. 2018 Feb 28;9:121-129. doi: 10.1016/j.conctc.2018.01.007. eCollection 2018 Mar.

3.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238. [Epub ahead of print]

PMID:
29637669
4.

Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.

von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, Shariat SF, Xylinas E, Roghmann F; Young Academic Urologists′ Working Group on Urothelial Cancer of the European Association of Urology.

Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3.

PMID:
29506940
5.

Lymphatic Drainage from Renal Tumors In Vivo: A Prospective Sentinel Node Study Using SPECT/CT Imaging.

Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Grivas N, Hendricksen K, Horenblas S, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A.

J Urol. 2018 Jun;199(6):1426-1432. doi: 10.1016/j.juro.2017.11.112. Epub 2017 Dec 6.

PMID:
29223390
6.

Navigation of Fluorescence Cameras during Soft Tissue Surgery-Is it Possible to Use a Single Navigation Setup for Various Open and Laparoscopic Urological Surgery Applications?

van Oosterom MN, Meershoek P, KleinJan GH, Hendricksen K, Navab N, van de Velde CJH, van der Poel HG, van Leeuwen FWB.

J Urol. 2018 Apr;199(4):1061-1068. doi: 10.1016/j.juro.2017.09.160. Epub 2017 Nov 22.

PMID:
29174485
7.

Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.

Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, Gontero P, Necchi A, Noon AP, van Rhijn BWG, Rink M, Roghmann F, Rouprêt M, Seiler R, Shariat SF, Qvick B, Babjuk M, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.

Eur Urol Focus. 2017 Oct 23. pii: S2405-4569(17)30206-7. doi: 10.1016/j.euf.2017.09.002. [Epub ahead of print]

PMID:
29074050
8.

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.

Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration group.

BJU Int. 2018 Feb;121(2):252-259. doi: 10.1111/bju.14020. Epub 2017 Oct 12.

PMID:
28940605
9.

Endo-Urological Techniques for Benign Uretero-Ileal Strictures Have Poor Efficacy and Affect Renal Function.

Fransen van de Putte EE, de Wall LL, van Werkhoven E, Heldeweg EA, Bex A, van der Poel HG, van Rhijn BWG, Horenblas S, Hendricksen K.

Urol Int. 2018;100(1):18-24. doi: 10.1159/000475508. Epub 2017 Aug 18.

PMID:
28817820
10.

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

de Bruijn RE, Kuusk T, Noe AP, Blank CU, Haanen JBAG, Hendricksen K, Horenblas S, Bex A.

Urology. 2017 Nov;109:127-133. doi: 10.1016/j.urology.2017.06.048. Epub 2017 Aug 2.

PMID:
28780300
11.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6. doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print]

PMID:
28753897
12.

FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

van de Putte EEF, Vegt E, Mertens LS, Bruining A, Hendricksen K, van der Heijden MS, Horenblas S, van Rhijn BWG.

Int Urol Nephrol. 2017 Sep;49(9):1585-1591. doi: 10.1007/s11255-017-1637-4. Epub 2017 Jul 3.

PMID:
28674853
13.

Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.

Bosschieter J, Vis AN, van der Poel HG, Moonen LM, Horenblas S, van Rhijn BWG, Pieters BR, Nieuwenhuijzen JA, Hendricksen K.

Eur Urol. 2018 Sep;74(3):369-375. doi: 10.1016/j.eururo.2017.05.054. Epub 2017 Jun 12.

PMID:
28619396
14.

Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.

Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, Shariat SF, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.

World J Urol. 2017 Sep;35(9):1401-1407. doi: 10.1007/s00345-016-1995-z. Epub 2017 Jan 10. Review.

PMID:
28074261
15.

Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.

Grivas N, Wit E, Pos F, de Jong J, Vegt E, Bex A, Hendricksen K, Horenblas S, KleinJan G, van Rhijn B, van der Poel H.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):347-354. doi: 10.1016/j.ijrobp.2016.10.016. Epub 2016 Oct 19.

PMID:
28068243
16.

Hybrid Surgical Guidance: Does Hardware Integration of γ- and Fluorescence Imaging Modalities Make Sense?

KleinJan GH, Hellingman D, van den Berg NS, van Oosterom MN, Hendricksen K, Horenblas S, Valdes Olmos RA, van Leeuwen FW.

J Nucl Med. 2017 Apr;58(4):646-650. doi: 10.2967/jnumed.116.177154. Epub 2016 Sep 29.

17.

Toward (Hybrid) Navigation of a Fluorescence Camera in an Open Surgery Setting.

KleinJan GH, van den Berg NS, van Oosterom MN, Wendler T, Miwa M, Bex A, Hendricksen K, Horenblas S, van Leeuwen FW.

J Nucl Med. 2016 Oct;57(10):1650-1653. Epub 2016 May 26.

18.

Toward Optimal Prediction of Prognosis in T1 Urothelial Carcinoma of the Bladder.

van Rhijn BW, Behrendt MA, Hendricksen K, van der Kwast TH.

Eur Urol. 2015 Nov;68(5):833-4;discussion 835-6. doi: 10.1016/j.eururo.2015.03.030. Epub 2015 Mar 23. No abstract available.

PMID:
25813690
19.

Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.

Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA.

J Urol. 2012 Apr;187(4):1195-9. doi: 10.1016/j.juro.2011.11.101. Epub 2012 Feb 14.

PMID:
22335860
20.

Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.

Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2011 Oct;60(4):713-20. doi: 10.1016/j.eururo.2011.07.010. Epub 2011 Jul 14.

PMID:
21794974
21.

The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations.

Arentsen HC, Hendricksen K, Hulsbergen-van de Kaa CA, Reddy G, Oosterwijk E, Alfred Witjes J.

Urol Oncol. 2012 Jan-Feb;30(1):64-8. doi: 10.1016/j.urolonc.2009.10.002. Epub 2009 Nov 27.

PMID:
19945311
22.

Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.

Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I.

J Urol. 2009 Oct;182(4):1313-7. doi: 10.1016/j.juro.2009.06.017. Epub 2009 Aug 14.

PMID:
19683278
23.

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party.

Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O.

World J Urol. 2009 Jun;27(3):319-24. doi: 10.1007/s00345-009-0384-2. Epub 2009 Feb 22.

24.

Experimental rat bladder urothelial cell carcinoma models.

Arentsen HC, Hendricksen K, Oosterwijk E, Witjes JA.

World J Urol. 2009 Jun;27(3):313-7. doi: 10.1007/s00345-009-0381-5. Epub 2009 Feb 15.

25.

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer.

Hendricksen K, van der Heijden AG, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Smits GA, Puri R, Gruijs S, Witjes JA.

World J Urol. 2009 Jun;27(3):337-42. doi: 10.1007/s00345-009-0382-4. Epub 2009 Feb 13.

26.

Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.

Hendricksen K, Gleason D, Young JM, Saltzstein D, Gershman A, Lerner S, Witjes JA.

J Urol. 2008 Jul;180(1):116-20. doi: 10.1016/j.juro.2008.03.031. Epub 2008 May 15.

PMID:
18485407
27.

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.

Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2008 May;53(5):984-91. doi: 10.1016/j.eururo.2007.12.033. Epub 2007 Dec 27.

PMID:
18248876
28.

Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy.

Hendricksen K, Molkenboer-Kuenen J, Oosterwijk E, Hulsbergen-van de Kaa CA, Witjes JA.

BJU Int. 2008 Apr;101(7):889-93. doi: 10.1111/j.1464-410X.2007.07407.x. Epub 2008 Jan 14.

29.

Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.

Hendricksen K, Witjes JA.

Curr Opin Urol. 2007 Sep;17(5):352-7. Review.

PMID:
17762630
30.
31.

False-positive lesions detected by fluorescence cystoscopy: any association with p53 and p16 expression?

Hendricksen K, Moonen PM, der Heijden AG, Witjes JA.

World J Urol. 2006 Nov;24(5):597-601. Epub 2006 Sep 22.

PMID:
17021825
32.

Intravesical gemcitabine: an update of clinical results.

Hendricksen K, Witjes JA.

Curr Opin Urol. 2006 Sep;16(5):361-6. Review.

PMID:
16905983
33.

Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.

Hendricksen K, Moonen PM, van der Heijden AG, Molkenboer-Kuenen J, Hulsbergen-van de Kaa CA, Witjes JA.

Clin Cancer Res. 2006 Apr 15;12(8):2597-601.

Supplemental Content

Loading ...
Support Center